These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 2386447)

  • 21. Motion-sickness medications for aircrew: impact on psychomotor performance.
    Paul MA; MacLellan M; Gray G
    Aviat Space Environ Med; 2005 Jun; 76(6):560-5. PubMed ID: 15945400
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Computerized task battery assessment of cognitive and performance effects of acute phenytoin motion sickness therapy.
    Chelen W; Ahmed N; Kabrisky M; Rogers S
    Aviat Space Environ Med; 1993 Mar; 64(3 Pt 1):201-5. PubMed ID: 8447800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of dimenhydrinate, cinnarizine and transdermal scopolamine on performance.
    Gordon CR; Gonen A; Nachum Z; Doweck I; Spitzer O; Shupak A
    J Psychopharmacol; 2001 Sep; 15(3):167-72. PubMed ID: 11565623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antimotion-sickness efficacy of scopolamine 12 and 72 hours after transdermal administration.
    Graybiel A; Cramer DB; Wood CD
    Aviat Space Environ Med; 1982 Aug; 53(8):770-2. PubMed ID: 7181807
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The T-maze continuous alternation task for assessing the effects of putative cognition enhancers in the mouse.
    Spowart-Manning L; van der Staay FJ
    Behav Brain Res; 2004 May; 151(1-2):37-46. PubMed ID: 15084419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of risperidone on psychometric and cognitive functions in healthy elderly volunteers.
    Allain H; Tessier C; Bentué-Ferrer D; Tarral A; Le Breton S; Gandon M; Bouhours P
    Psychopharmacology (Berl); 2003 Feb; 165(4):419-29. PubMed ID: 12459926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Scopolamine alone or combined with ephedrine in seasickness: a double-blind, placebo-controlled study.
    Laitinen LA; Tokola O; Gothoni G; Vapaatalo H
    Aviat Space Environ Med; 1981 Jan; 52(1):6-10. PubMed ID: 7011299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Human assay of antimotion sickness drugs.
    Graybiel A; Wood CD; Knepton J; Hoche JP; Perkins GF
    Aviat Space Environ Med; 1975 Sep; 46(9):1107-18. PubMed ID: 1100039
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transdermal scopolamine: a review of its effects upon motion sickness, psychological performance, and physiological functioning.
    Parrott AC
    Aviat Space Environ Med; 1989 Jan; 60(1):1-9. PubMed ID: 2647072
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the effects of a selective muscarinic receptor antagonist and hyoscine (scopolamine) on motion sickness, skin conductance and heart rate.
    Golding JF; Stott JR
    Br J Clin Pharmacol; 1997 Jun; 43(6):633-7. PubMed ID: 9205824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drugs, memory, and metamemory: a dose-effect study with lorazepam and scopolamine.
    Mintzer MZ; Griffiths RR
    Exp Clin Psychopharmacol; 2005 Nov; 13(4):336-47. PubMed ID: 16366764
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Testosterone potentiates scopolamine-induced disruptions of nonspatial learning in gonadectomized male rats.
    Leonard ST; Moerschbaecher JM; Winsauer PJ
    Exp Clin Psychopharmacol; 2007 Feb; 15(1):48-57. PubMed ID: 17295584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintaining alertness and performance during sleep deprivation: modafinil versus caffeine.
    Wesensten NJ; Belenky G; Kautz MA; Thorne DR; Reichardt RM; Balkin TJ
    Psychopharmacology (Berl); 2002 Jan; 159(3):238-47. PubMed ID: 11862356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effects of scopolamine and cyclizine on visual-vestibular interaction in humans.
    Gowans J; Matheson A; Darlington CL; Smith PF
    J Vestib Res; 2000; 10(2):87-92. PubMed ID: 10939683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Scopolamine induced deficits in a battery of rat cognitive tests: comparisons of sensitivity and specificity.
    Hodges DB; Lindner MD; Hogan JB; Jones KM; Markus EJ
    Behav Pharmacol; 2009 May; 20(3):237-51. PubMed ID: 19436198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Psychomotor, physiological and cognitive effects of scopolamine and ephedrine in healthy man.
    Nuotto E
    Eur J Clin Pharmacol; 1983; 24(5):603-9. PubMed ID: 6873137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
    Johnson MW; Suess PE; Griffiths RR
    Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute cognitive effects of standardised Ginkgo biloba extract complexed with phosphatidylserine.
    Kennedy DO; Haskell CF; Mauri PL; Scholey AB
    Hum Psychopharmacol; 2007 Jun; 22(4):199-210. PubMed ID: 17457961
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effects of the selective muscarinic M3 receptor antagonist darifenacin, and of hyoscine (scopolamine), on motion sickness, skin conductance & cognitive function.
    Golding JF; Wesnes KA; Leaker BR
    Br J Clin Pharmacol; 2018 Jul; 84(7):1535-1543. PubMed ID: 29522648
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of transdermal scopolamine upon psychological test performance at sea.
    Parrott AC; Jones R
    Eur J Clin Pharmacol; 1985; 28(4):419-23. PubMed ID: 4029247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.